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Chronic obstructive pulmonary disease (COPD) is characterized by a decline of lung function and symptoms such as chronic
bronchitis and emphysema leading from lung tissue destruction. Increased activity of matrix metalloproteinases (MMPs) and an
imbalance between MMPs and their tissue inhibitors (TIMPs) are considered as factors influencing the pathogenesis of COPD.
We investigated the role of genetic polymorphism and expression level of MMP-9 and concentration of its complexes with TIMPs
in the development of COPD among Polish patients. We analyzed SNP in the promoter region ofMMP-9 gene (rs3918242) using
PCR-RFLP method among 335 COPD patients and 309 healthy individuals. Additionally, 60 COPD patients and 61 controls were
tested for copy number variants (CNV) ofMMP-9 (by quantitative real-time PCR) and serum levels of MMP-9 and its complexes
with TIMP1 and TIMP2 (using ELISA). All subjects were analyzed for lung function using spirometry (FEV1% and FEV1/FVC
parameters). We observed that allele and genotype frequencies of the SNP rs3918242, as well as the number of gene copies, were
similar in COPD patient and controls groups. Serum levels of MMP-9 and MMP-9/TIMP1 complex were significantly higher in
COPD patients in comparison to controls groups, although independently of analyzed gene polymorphisms. Additionally, the
significant inverse relationships between parameters of lung function (FEV1% and FEV1/FVC) and proteins level were found in
ridge regression models, especially we found that FEV1% decreased when MMP-9 level increased in controls and patients with
COPDgroup. In conclusion, we found that COPDpatientswere predisposed to producemoreMMP-9 andMMP-9/TIMP1 complex
than healthy individuals. This phenomenon is probably associated with the disease-related lung environment but not with genetic
features of theMMP-9.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is character-
ized by airflow limitation through the respiratory tract that
is not fully reversible. The disease is associated with lung
inflammatory response to harmful gases and dust, including
cigarette smoke [1]. Moreover, COPD patients are affected
with a pulmonary emphysema leading from lung tissue
destruction and the decline of lung function as a result
[2, 3]. Thus, it is generally believed that mechanism under-
lying the COPD pathogenesis is dysregulation of proteases
activity, especially when imbalance between proteases and
antiproteases develops because of either the higher activity of
proteases or dysfunction of protease inhibitors [3–5].
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Table 1: Characteristics of the analyzed groups.
Groups (N) Age Sex FEV1 FEV1/FVC Smokers
(years) (women/men) (% predicted) (% predicted) (%)
COPD (335) 67.9 ± 9.2 248/87∗ 55.5 ± 18.5∗ 52.2 ± 16.0∗ 100∗
CTR (309) 68.0 ± 6.6 80/229 91.7 ± 22.8 89.2 ± 25.8 35.5
CTR smokers (110) 68.4 ± 5.2 73/37 93.3 ± 22.0 91.1 ± 19.5 100
CTR non-smokers (199) 65.8 ± 9.6 157/42 91.0 ± 23.6 88.1 ± 28.7 0
COPD# (60) 70.4 ± 9.0 13/47∗ 46.6 ± 18.5∗ 58.1 ± 16.4∗ 100∗
CTR# (61) 67.8 ± 6.7 46/15 90.4 ± 22.5 92.6 ± 23.2 37.7
CTR smokers# (23) 67.7 ± 5.6 15/8 93.2 ± 21.9 88.2 ± 16.4 100
CTR non-smokers# (38) 67.9 ± 7.6 31/7 90.6 ± 22.0 90.7 ± 18.0 0
N, numbers of individuals; COPD, chronic obstructive pulmonary disease groups; CTR, control group; # , groups for CNV and protein levels analyses; FEV1,
forced expiratory volume in 1 second; FEV1/FVC, Tiffeneau-Pinelli index; ratio of forced expiratory volume in 1 second and forced vital capacity; ∗, difference
to the control group statistically significant at the level of p<0.00001.
It is widely accepted that metalloproteinases (MMPs)
engaged in the COPD pathogenesis degrade matrix proteins
(elastin, collagen) and the metalloproteinase 9 (MMP-9)
plays a principal role in this process [6]. The protease is
a type IV collagen-degrading enzyme, and its presence is
required for adequate matrix processing and lung repair [7,
8]. However, MMP-9 oversecretion may cause an unwanted
degradation of lung tissue, and this may be one of the causes
of COPD [6], probably due to the tobacco smoke stimuli [4].
The increased expression of MMP-9 may be associated with
an increasing level of gene promoter activity. In particular,
the -1562C/T polymorphism (rs3918242) in theMMP-9 gene
promoterwas found to be associatedwithMMP-9 expression,
and the -1562T allele leads to higher transcription activity [9].
In this study, we evaluated the role of MMP-9 gene -
1562C/T polymorphism, as well as MMP-9 protein and its
complexes with TIMP levels, in COPDdevelopment in Polish
patients.
2. Materials and Methods
2.1. COPDPatient andControls Group. Threehundred thirty-
five patients (248 males and 87 females) with COPD were
enrolled in the study. All subjects underwent routine diag-
nosis including the spirometry result and FEV1/FVC ratio
reduction below the lower limit of the norm. The spirometry
test was performed twice, before the bronchodilator appli-
cation (400𝜇g of salbutamol) and after (15 – 20 minutes).
The outcome of the bronchial relaxation trial performed in
thatway should be negative. Patients with alpha-1- antitrypsin
deficiency, coexistence of asthma, and COPD or with earlier
history of bronchial asthma as well as patients who have
never smokedwere excluded from the study. All patients were
recruited from the inpatient and outpatient populations of
the University Hospital in Cracow, Specialized Hospital of
Ministry of Internal Affairs and Administration (MSWiA)
in Głuchołazy and Department of Pulmonology, Opole
Voivodeship Hospital.
Three hundred and nine unrelated healthy volunteers (80
men and 229women) not diagnosed for COPDnor any other
lung disease and exhibiting normal lung function (mean
FEV1% of 91.7%) served as a control group. To determine the
effect of an exposure to tobacco smoke on analyzed factors,
the controls were divided into subgroups of those with
tobacco smoking history (110 current and former smokers)
and those who had never smoked (199 never smokers).
For CNVand protein levels examination, 60 patients with
COPD and 61 control individuals (23 smokers and 38 never
smokers) were randomly selected.
All members of the patients and control group were of
Polish Caucasians ethnicity, and detailed characteristics are
shown in Table 1.
The project was approved by the Ethics Committee of
Opole Voivodship. Signed informed consent was obtained
from all persons tested.
2.2. DNA Isolation and SNP and CNV Genotyping. gDNA
was extracted from whole blood using the GeneMA-
TRIX Quick Blood DNA Purification Kit (EURx, Poland)
following the manufacturer’s instructions. The -1562C/T
polymorphism of theMMP-9 gene (rs3918242) was typed by
the PCR-RFLP method as described previously [9]. Briefly,
polymerase chain reactions were carried out in 20 𝜇l of
solution containing a standard PCR buffer, 200 ng of tested
DNA, 1 U of Taq Polymerase (Invitrogen, Brazil), 2mM
MgCl2, 200 𝜇MdNTPs (Invitrogen, Brazil), and 1 𝜇Mof each
primer (forward: 5󸀠-GCCTGGCACATAGTAGGCCC-3󸀠 and
reverse: 5󸀠-CTTCCTAGCCAGCCGGCATC-3󸀠). Amplifica-
tions were performed under the following conditions: 2min
at 94∘C; 30 cycles of 30 s at 94∘C; 30 s at 60∘C; 60 s at 72∘Cwith
the last elongation step of 7min at 72∘C. The PCR product
was digested with 1 U of SphI restriction enzyme (Fermentas,
USA) for 3 h at 37∘C (435 bp amplicons containing a T
allele were cut into two fragments of 244 bp and 191 bp).
All digested products were electrophoresed on 3% agarose
gel and visualized in a UV transilluminator using ethidium
bromide staining.
TheCNVpolymorphismwas typed using the quantitative
polymerase chain reaction (qPCR) by TaqMan CopyNumber
Assays (Applied Biosystems of Life Technology, Foster City,
CA) according to the manufacturer’s protocol in total reac-
tion volume of 20 𝜇L (contained 20 ng gDNA, 1x probes for
both the target (hs 00238040cn) and reference gene (RNase P)
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and 1x TaqMan Genotyping Master Mix). The PCR program
was processed as follows: 95∘C for 10min, 40 cycles of 95∘C
for 15 s, and 60∘C for 1min. Data were collected at the end of
each cycle. All DNA samples were run in triplicate to ensure
accurate results. Then, the CopyCaller Software (Applied
Biosystems by Life Technology, CA) was used to analyze copy
numbers of the tested gene in the samples.
2.3. Analysis of Protein Levels. Theserum level ofMMP-9was
measured using the Quantikine enzyme-linked immunosor-
bent assay (ELISA), and serum concentrations of its com-
plexes with TIMP1 and TIMP2 were determined by DuoSet
ELISAs (all R&D, MN, USA). All analyses were performed
according to the manufacturer’s instruction using serum
samples either nondiluted (forMMP-9) or diluted of 100-fold
(for complexes). The absorbance was read with the Epoch
microplate reader (BioTech, Winooski, VT, USA) at 450 nm
as the primary wave length and 540 nm as the reference.
Concentrations of proteins in samples were calculated with
the equation of the standard curve using Gen5 software
(BioTech, Winooski, VT, USA).
2.4. Statistical Analysis. Deviation of the genotype counts
from Hardy-Weinberg equilibrium was tested using the 𝜒2-
test and EpiInfo software. Differences in alleles and geno-
types distribution between controls and patient groups were
estimated using the two-tailed Fisher’s exact test and 𝜒2-
test with Yate’s correction, respectively. GraphPad InStat 3
software was used for distribution analyses. Moreover, the
multiple inheritance models (codominant, dominant, reces-
sive, overdominant, and log-additive) via logistic regression
with binary response (a disease status) using SNPstats web
tool (https://www.snpstats.net) were estimated. In protein
levels, before relevant statistical comparison of all obtained
data, the distribution of values was checked with the method
of Shapiro-Wilk. One-way analysis of variance (ANOVA) was
used to assess differences between obtained values of protein
concentration. Subsequently, when significant interactions in
ANOVA were identified, appropriate Tukey post hoc tests
were applied. For the analysis of relationship between protein
levels and lung function parameters, a multiple ridge regres-
sion model was used. For analysis of COPD development
predictors, a logistic regression fitted with the disease status
as a response variable was used and as covariates were
selected: SNP rs3918242, CNV, gender, smoking status and
levels of MMP-9, and its complexes with TIMP1 and TIMP2.
These statistical analyses were performed using Statistica v.12
(StatSoft, Inc., OK, USA). In all analyses, p values ≤0.05 were
considered significant.
3. Results
In total, 335 patients affected with COPD and 309 healthy
individuals were typed for SNP rs3918242 in the promoter of
the gene encoding MMP-9. The observed genotype frequen-
cies were very close to the values expected for both cases and
controls populations according to the Hardy-Weinberg equi-
librium (p<0.05, data not shown). There were no significant
differences in alleles and genotypes frequency distribution
between the COPD patients and controls (Table 2). When
controls were divided into two groups according to the smok-
ing status, nonsignificantly lower -1562C allele frequency
in smokers was observed (83.2% versus 87.1% in COPD
group, p=0.09; Table 2). Additionally, no differences between
patients with COPD and controls in genotype frequencies
distribution were observed in dominant (CC versus CT+TT),
recessive (CC+CT versus TT), and overdominant (CC+TT
versus CT) models of inheritance (Table 1S in Supplementary
Material).
The numbers ofMMP-9 gene copies were analyzed in the
groups of 60 randomly selected patients with COPD and 61
healthy volunteers. We found that 85.0% of COPD patients
and 82.0% of controls had 2 copies of the MMP-9 gene.
Additionally, we also found individuals with 1 copy (3.3% and
4.9% in patients and controls, respectively), 3 copies (11.7%
and 9.9% in patients and controls, respectively), and 4 copies
(3.2%of controls). However, no significant difference in CNV
frequency between COPDpatients and the control group was
found (Table 2).
We also evaluated the levels of MMP-9 and its complexes
with TIMP1 and TIMP2 in serum of COPD patients and
controls (the same as selected for CNV) (Table 3). We found
that the mean serumMMP-9 levels in the COPD group were
significantly higher in comparison with the control group
(149.0 ng/ml versus 26.5 ng/ml; p < 0.0001), as well as those
of the controls subgroups with smoking status (27.5 ng/ml
in smokers and 25.9 ng/ml in never smokers, p = 0.37 for
comparison between both control subgroups). In contrast,
there were no significant differences in the mean serum
levels of MMP-9/TIMP1 and MMP-9/TIMP2 between the
COPD patients and controls, except a significant difference
between COPD patients and total controls in levels of MMP-
9/TIMP1 complex (3146.8 pg/ml versus 2970.1 pg/ml, p =
0.04). Additionally, serum of control smokers contained a
significantly higher level of this complex in comparison to
control nonsmokers (3135.8 pg versus 2869.8 pg, respectively;
p = 0.03; Table 3).
In particular, in systematic comparison between SNP
rs3918242, CNV genotypes, and serum MMP-9, MMP-
9/TIMP1 and MMP-9/TIMP2 levels showed no statistically
significant differences (Table 4). However, the COPDpatients
with 2 copies of the MMP-9 gene exhibited lower MMP-9
serum level in comparison to the combined group of patients
with 1 or more than 2 copies of the gene (142.9 ng/ml versus
186.8 ng/ml, p = 0.09; Table 4).
Generally, COPD patients were characterized by sig-
nificantly lower lung function parameters (FEV1% and
FEV1/FVC) in comparison to controls (Table 1). This phe-
nomenon continued to be observed after division of groups
according to SNP rs3918242 and CNV genotypes. On the
other hand, MMP-9 genotypes-related intragroup compar-
isons did not reveal any significant differences (Table 4).
In addition, interactions between lung function param-
eters and levels of MMP-9, MMP-9/TIMP1, and MMP-
9/TIMP2 were analyzed using ridge regression modeling.
In controls group, an increment in MMP-9 levels was
significantly associated with lower FEV1% (when MMP-9
level increases by 1 unit, the FEV1% decreases by 0.86). The
4 BioMed Research International
Ta
bl
e
2:
A
lle
le
sa
nd
ge
no
ty
pe
sd
ist
rib
ut
io
ns
of
-1
56
2C
/T
SN
P
of
M
M
P-
9
ge
ne
(r
s3
91
82
42
)a
nd
co
py
nu
m
be
rv
ar
ia
bi
lit
y
of
M
M
P-
9
ge
ne
in
C
O
PD
pa
tie
nt
an
d
he
al
th
y
co
nt
ro
lg
ro
up
s.
M
M
P-
9
ge
ne
po
ly
m
or
ph
ism
s
Fr
eq
ue
nc
y(
N
um
be
ro
fp
os
iti
ve
)
p
va
lu
e
C
O
PD
N
=3
35
/6
0#
CT
R
N
=3
09
/6
1#
CT
R
sm
ok
er
s
N
=1
10
/2
3#
CT
R
no
n-
sm
ok
er
s
N
=1
99
/3
8#
p 1
p 2
p 3
p 4
rs
39
18
24
2
(-
15
62
C/
T)
A
lle
le
s
C
87
.1
(5
83
)
85
.2
(5
26
)
83
.2
(1
83
)
86
.1
(3
43
)
0.
36
0.
09
0.
76
0.
34
T
12
.9
(8
7)
14
.8
(9
2)
16
.8
(3
7)
13
.8
(5
5)
G
en
ot
yp
es
C
C
76
.2
(2
55
)
73
.2
(2
26
)
69
.1
(7
6)
75
.3
(1
50
)
0.
61
0.
34
0.
36
0.
43
CT
21
.8
(7
3)
23
.9
(7
4)
28
.2
(3
1)
21
.6
(4
3)
TT
2.
0
(7
)
2.
9
(9
)
2.
7
(3
)
10
.9
(6
)
CN
V
#
1c
op
y
3.
3
(2
)
4.
9
(3
)
0.
0
(0
)
7.9
(3
)
0.
51
0.
31
0.
41
0.
31
2
co
pi
es
85
.0
(5
1)
82
.0
(5
0)
91
.3
(2
1)
76
.3
(2
9)
3
co
pi
es
11.
7
(7
)
9.9
(6
)
4.
3
(1
)
13
.2
(5
)
4
co
pi
es
0
(0
)
3.
2
(2
)
4.
3
(1
)
2.
6
(1
)
N
,n
um
be
ro
fi
nd
iv
id
ua
ls;
CO
PD
,c
hr
on
ic
ob
str
uc
tiv
e
pu
lm
on
ar
y
di
se
as
e
gr
ou
ps
;C
TR
,c
on
tro
lg
ro
up
;𝑝
1,
CO
PD
pa
tie
nt
sv
er
su
sC
TR
;𝑝
2,
CO
PD
pa
tie
nt
s
ve
rs
us
CT
R
sm
ok
er
s;
𝑝
3,
CO
PD
pa
tie
nt
s
ve
rs
us
CT
R
no
ns
m
ok
er
s;
𝑝
4,
CT
R
sm
ok
er
sv
er
su
sC
TR
no
n-
sm
ok
er
s;
# ,
CN
V
an
al
ys
es
we
re
pe
rfo
rm
ed
on
60
CO
PD
pa
tie
nt
sa
nd
61
co
nt
ro
ls
(2
3
sm
ok
er
sa
nd
38
no
ns
m
ok
er
s)
.
BioMed Research International 5
Ta
bl
e
3:
M
M
P-
9,
M
M
P-
9/
TI
M
P1
,a
nd
M
M
P-
9/
TI
M
P2
pr
ot
ei
ns
le
ve
li
n
se
ru
m
of
C
O
PD
pa
tie
nt
an
d
he
al
th
y
co
nt
ro
lg
ro
up
s.
Pr
ot
ei
ns
le
ve
ls
G
ro
up
s
p
va
lu
e
C
O
PD
pa
tie
nt
s
N
=6
0
CT
R
N
=6
1
CT
R
sm
ok
er
s
N
=2
3
CT
R
no
n-
sm
ok
er
s
N
=3
8
p 1
p 2
p 3
p 4
M
M
P-
9
[n
g/
m
l]
14
9.0
±
72
.3
26
.5
±
6.
5
27
.5
±
7.9
25
.9
±
5.
6
<
0.
00
00
1
<
0.
00
00
1
<
0.
00
00
1
0.
37
M
M
P-
9/
TI
M
P1
[p
g/
m
l]
31
46
.8
±
49
1.9
29
70
.1
±
48
5.
1
31
35
.8
±
18
0.
4
28
69
.8
±
57
8.
8
0.
04
0.
9
0.
10
0.
03
M
M
P-
9/
TI
M
P2
[n
g/
m
l]
6.
1±
4.
7
6.
1±
2.
0
5.
8
±
1.4
6.
3
±
2.
3
0.
9
0.
6
0.
82
0.
31
N
,n
um
be
ro
fi
nd
iv
id
ua
ls;
CO
PD
,c
hr
on
ic
ob
str
uc
tiv
e
pu
lm
on
ar
y
di
se
as
e
gr
ou
ps
;C
TR
,c
on
tro
lg
ro
up
;𝑝
1,
CO
PD
pa
tie
nt
sv
er
su
sC
TR
;𝑝
2,
CO
PD
pa
tie
nt
s
ve
rs
us
CT
R
sm
ok
er
s;
𝑝
3,
CO
PD
pa
tie
nt
s
ve
rs
us
CT
R
no
ns
m
ok
er
s;
𝑝
4,
CT
R
sm
ok
er
sv
er
su
sC
TR
no
ns
m
ok
er
s.
6 BioMed Research International
Ta
bl
e
4:
M
M
P-
9
ge
ne
po
ly
m
or
ph
ism
si
m
pa
ct
on
M
M
P-
9,
M
M
P-
9/
TI
M
P1
an
d
M
M
P-
9/
TI
M
P2
pr
ot
ei
ns
le
ve
li
n
se
ru
m
of
C
O
PD
pa
tie
nt
an
d
he
al
th
y
co
nt
ro
lg
ro
up
s.
Pr
ot
ei
ns
le
ve
ls
G
en
ot
yp
es
G
ro
up
s
p
va
lu
e
C
O
PD
pa
tie
nt
s
N
=6
0
CT
R
N
=6
1
CT
R
sm
ok
er
s
N
=2
3
CT
R
no
n-
sm
ok
er
s
N
=3
8
p 1
p 2
p 3
p 4
M
M
P-
9
[n
g/
m
l]
C
al
le
le
14
9.9
±
72
.8
26
.5
±
6.
8
27
.6
±
8.
3
25
.9
±
5.
8
<
0.
00
00
1
<
0.
00
00
1
<
0.
00
00
1
1.0
T
al
le
le
13
0.
7
±
35
.9
27
.6
±
8.
3
30
.4
±
8.
3
22
.6
±
6.
3
<
0.
00
00
1
<
0.
00
00
1
<
0.
00
00
1
0.
76
C
C
15
2.
9
±
76
.9
26
.0
±
5.
6
23
.9
±
5.
9
26
.7
±
5.
4
<
0.
00
00
1
<
0.
00
00
1
<
0.
00
00
1
1.0
CT
13
0.
7
±
35
.9
27
.7
±
9.3
31
.0
±
8.
9
20
.5
±
5.
9
<
0.
00
00
1
<
0.
00
00
1
<
0.
00
00
1
1.0
TT
-
27
.4
±
2.
5
26
.9
±
1.8
27
.9
±
3.
9
no
tt
es
te
d
no
tt
es
te
d
no
tt
es
te
d
0.
72
2
co
pi
es
14
2.
9
±
64
.9
27
.1
±
6.
5
27
.5
±
8.
3
26
.8
±
5.
0
<
0.
00
00
1
<
0.
00
00
1
<
0.
00
00
1
1.0
1a
nd
>
2
co
pi
es
18
6.
8
±
10
1.8
24
.2
±
6.
8
27
.6
±
1.7
23
.5
±
7.4
<
0.
00
00
1
0.
00
6
<
0.
00
00
1
1.0
M
M
P-
9/
TI
M
P1
[p
g/
m
l]
C
al
le
le
3 1
46
.8
±
49
2.
0
29
51
.4
±
49
6.
1
31
25
.0
±
18
2.
5
28
50
.1
±
58
8.
3
0.
14
1.0
0.
02
0.
18
T
al
le
le
32
32
.3
±
35
4.
0
30
72
.8
±
52
3.
1
31
81
.7
±
17
3.
3
28
70
.6
±
85
6.
2
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
C
C
31
31
.7
±
51
3.
8
29
20
.0
±
46
4.
0
30
76
.2
±
18
0.
3
28
69
.7
±
51
6.
3
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
CT
32
32
.3
±
35
4.
0
30
31
.8
±
57
8.
9
31
69
.6
±
18
1.1
27
28
.9
±
10
03
.9
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
TT
-
32
36
.7
±
111
.6
32
48
.4
±
14
7.3
32
29
.0
±
12
2.
9
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
2
co
pi
es
31
32
.9
±
53
2.
7
29
68
.6
±
51
2.
7
31
29
.6
±
18
7.2
28
52
.0
±
63
3.
6
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
1a
nd
>
2
co
pi
es
32
25
.9
±
54
.5
29
76
.9
±
35
2.
6
32
00
.6
±
74
.2
29
27
.3
±
37
3.
4
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
M
M
P-
9/
TI
M
P2
[n
g/
m
l]
C
al
le
le
6.
2
±
4.
2
6.
2
±
2.
0
5.
8
±
1.4
6.
5
±
2.
3
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
T
al
le
le
9.4
±
8.
2
5.
7
±
1.8
5.
9
±
1.3
5.
5
±
2.
6
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
C
C
5.
6
±
2.
8
6.
3
±
2.
2
5.
6
±
1.6
6.
5
±
2.
3
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
CT
9.4
±
8.
2
6.
0
±
1.8
6.
0
±
1.3
6.
2
±
2.
8
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
TT
-
4.
5
±
1.2
5.
1±
0.
2
3.
9
±
1.7
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
2
co
pi
es
6.
3±
4.
5
6.
0
±
1.6
5.
8
±
1.4
6.
0
±
1.7
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
1a
nd
>
2
co
pi
es
5.
5±
0.
4
6.
8
±
3.
5
5.
0
±
0.
5
7.1
±
3.
8
no
tt
es
te
d
(A
N
O
VA
p>
0.
05
)
N
,n
um
be
ro
fi
nd
iv
id
ua
ls;
CO
PD
,c
hr
on
ic
ob
str
uc
tiv
e
pu
lm
on
ar
y
di
se
as
e
gr
ou
ps
;C
TR
,c
on
tro
lg
ro
up
;𝑝
1,
CO
PD
pa
tie
nt
sv
er
su
sC
TR
;𝑝
2,
CO
PD
pa
tie
nt
s
ve
rs
us
CT
R
sm
ok
er
s;
𝑝
3,
CO
PD
pa
tie
nt
s
ve
rs
us
CT
R
no
ns
m
ok
er
s;
𝑝
4,
CT
R
sm
ok
er
sv
er
su
sC
TR
no
ns
m
ok
er
s.
BioMed Research International 7
increase of levels of complexes MMP-9/TIMP1 and MMP-
9/TIMP2 was negatively related to FEV1/FVC parameter,
which decreases by 0.01 and 2.50 with each additional unit of
MMP-9/TIMP1 and MMP-9/TIMP2, respectively (Table 5).
In patients with COPD group, the model showed a significant
negative relationship between MMP-9 levels and values of
both lung function parameters (FEV1% decreases by 0.06
and FEV1/FVC decreases by 0.04 for increased by 1-unit
protein level). Additionally, MMP-9/TIMP1 complex level
was positively related to FEV1/FVC, which increases by 0.006
for every 1-unit increasing in the complex level (Table 5).
Table 6 shows a logistic regression analysis of potential
predictors of COPD development; the variables found to
be significantly associated with the COPD in univariate
logistic regression analysis were gender (OR = 8.16, 95%
CI = 5.73-11.61, p < 0.0001), smoking (OR = 606.04, 95%
CI = 83.96-4374.76, p < 0.0001), and MMP-9 protein level
(OR = 1.10, 95% CI = 1.06-1.14, p < 0.0001). Taking these
covariates with significant association in univariable analysis
into multivariable analysis revealed that MMP-9 serum level
was considered as a potential independent risk factor (OR =
1.12, 95% CI = 1.03-1.23, and p = 0.001).
4. Discussion
It is postulated that the action of MMPs can lead to tis-
sue degradation and emphysema and provide physiological
remodeling of lung tissue, but when misregulated, may
be associated with COPD development and severity. The
protease-antiprotease imbalance is at the focus point of
COPDpathogenesis hypothesis [10]. A classic example of this
phenomenon is deficiency of the serine protease inhibitor, 𝛼1-
antitrypsin, which is commonly known as a major genetic
factor in emphysema development [11] but accounts for only
3% of COPD patients. Thus, it seems that the crucial role in
the pathogenesis of COPD is played by other proteases and
their specific inhibitors. The role played by MMP-9 and its
inhibitors TIMP1 and TIMP2 seems to be particularly impor-
tant [9, 11].MMP-9 is an enzyme secreted by several cell types,
including neutrophils and airway epithelial cells, as well as
macrophages, which can be involved in COPD pathogenesis.
In an attempt to resolve that issue, we performed analysis
of genetic and physiological features of MMP-9 in COPD
pathogenesis.
In genetic analysis, our results suggest that there is
no association between alleles and genotypes of the SNP
rs3918242 (-1562C/T) andCOPD susceptibility among Polish
COPD patients. This finding is in accordance with other
studies on the Caucasian population with the exception of
non-HispanicWhites andHispanic veterans, in case of whom
it was concluded that TT genotypes constitute a risk factor for
COPD development [12]. In contrast, the -1562T allele seems
to be associated with the disease in Asians, but with some
ambiguity in Koreans the T allele seems to play a protective
role (reviewed by Stankovic et al. [13]). Nevertheless, two
meta-analyses showed that SNP rs3918242 is associated with
the risk of COPD [14, 15].
Despite this contradictory role of mentioned polymor-
phism [6, 12, 14–17], this SNP is most widely analyzed SNP of
MMP-9 gene and it is considered as the functional promoter
polymorphism.When T allele is present, the higher promoter
activity has been shown [9, 13], and it also was shown that
COPD patients with the CT genotype expressed a higher
serum level of MMP-9 [18]. Our results did not support this
finding: we confirmed the results obtained by other authors
[19–22] that the MMP-9 level in serum of COPD patients
is higher in serum than in healthy controls, but we found
that the difference does not depend on the SNP rs3918242,
as well as on the number of MMP-9 gene copies (Table 4).
Thus, we hypothesize that the increased secretion of MMP-9
in COPD patients may be a result of the disease-specific lung
microenvironment, and this phenomenon could be explained
by an inducible character of this enzyme [4].
The MMP is not produced by resident pulmonary ma-
crophages in healthy lung; in contrast, in the COPD-related
lung microenvironment, immunocompetent cells are the
main source of MMP-9 [23]. It is known that stimulation of
neutrophils leads to release of MMP-9 [24] and the alveolar
macrophages from COPD patients produce more MMP-9
thanmacrophages from healthy controls in response to either
inflammatory stimuli or cigarette smoke [25]. Therefore, it
is suggested that MMP-9 serum level is associated with the
disease severity and it is likely that it negatively correlates
with lung function parameters (FEV1%, FEV1/FVC) [20,
26, 27]. In a compliance with this indication, we found
the inverse relationship between MMP-9 level and FEV1%
in both groups (patients with COPD and controls) and
additionally with FEV1/FVC in COPD patients. Because of
this, it cannot be excluded that MMP-9 is a biomarker for
the presence and clinical course of COPD. Moreover, our
result suggests that the enzyme level possesses a capability to
be an independent predictor of the disease development. In
aspect of this finding, it should be kept in mind that COPD is
particularly associatedwith smoking (the variable included to
our regression analysis). It is known that polymorphonuclear
leukocytes from healthy controls could be stimulated by
cigarette smoke to secrete MMP-9 at a level similar to the one
found in COPD patients [4], but we did not find the different
concentrations of MMP-9 in smokers and nonsmokers sub-
groups of controls. Nevertheless, it cannot be excluded that
elevated level of MMP-9 accompanied smoking. Therefore,
our regression observations need to be replicated, in the
same or other populations, in order to consider MMP-9 as
the biomarker and/or the predictor of COPD to reflect the
complex role of MMP-9 in COPD.
MMP-9 is inhibited by the tissue inhibitors of metallo-
proteinase (TIMP1) and so the imbalance between MMP-9
and TIMP1 ratio could be involved in COPD pathogenesis
[28]. Herein, in complement of the MMP-9 and TIMP1 ratio
analysis [28, 29], we demonstrate that the concentration of
the MMP-9/TIMP1 complex in the serum of COPD patients
is higher than that in healthy controls, which corroborates
the findings of other authors [30]. More complexes of MMP-
9/TIMP1 could be delivered by increased secretion of MMP-
9, but it was also found that COPD patients exhibited a
significantly higher level of unbound TIMP1 ([29, 30] and
our unpublished data). Additionally, Lo et al. identified
that smokers who exhibit the airway hyperresponsiveness
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Table 6: Logistic regression analysis for prediction of COPD.
Predictor Univariable Multivariable
P OR 95% CI P OR 95% CI
Gender <0.0001 8.16 5.73-11.61 0.72 1.22 0.06-26.24
Smoking status <0.0001 606.04 83.96-4374.76 1.0 - -
MMP-9 level <0.0001 1.10 1.06-1.14 0.001 1.12 1.03-1.23
MMP-9/TIMP1 level 0.06 1.00 1.00-1.00
MMP-9/TIMP2 level 0.93 1.00 0.90-1.12
SNP rs3918242 0.34 0.16 0.85-1.59
CNV 0.58 0.81 0.38-1.72
N, number of individuals; COPD, chronic obstructive pulmonary disease groups; CTR, control group; MMP-9, metalloproteinase 9; MMP-9/TIMP1, complex
of metalloproteinase 9 and tissue inhibitor of metalloproteinase 1; MMP-9/TIMP2, complex of metalloproteinase 9 and tissue inhibitor of metalloproteinase 2;
CNV, copy number variation.
produce increased level of MMP-9 to TIMP1, and the authors
concluded that this finding indicates a new predictor to
identify smokers vulnerable to COPD [31]. Interestingly,
our results suggest that the MMP-9/TIMP1 complex con-
centration seems to be dependent on cigarette smoking
(controls smokers exhibit a significantly higher level than
nonsmokers).
Several limitations of the present study should be taken
into account. A potential important weakness is the design of
the study performed for protein levels analysis. Wemeasured
MMP-9 and its complexes with TIMP1 and TIMP2 only at the
protein level in blood, but not in situ using either sputum or
bronchoalveolar lavage, which should better reflect the phe-
nomena occurring in the lungs. Nevertheless, no significant
difference between serumand induced sputumconcentration
of MMP-9 was found in a previous study [32]. In addition,
despite the fact that in our study groups gender mismatching
occurred, no intergender difference in analyzed factors was
observed (Figures 1S-5S in Supplementary Material), which
is in accordance with the study by de Torres et al. [33],
who found similar level of MMP-9 in women and men.
Nevertheless, it seems that COPD phenotype depends on
sex and men have milder dyspnea and better quality of life
than women with a similar degree of airflow obstruction
[33]. On the other hand, as we showed male gender could be
considered as potential risk factor for COPD development.
5. Conclusions
We found that patients affected with COPDwere predisposed
to produce more MMP-9 and MMP-9/TIMP1 complex than
healthy individuals. This phenomenon is probably associated
with the disease-related lung environment, but not with
genetic features of MMP-9 gene. Moreover, to the best
of our knowledge, this is the first study in which copy
number variation of theMMP-9 gene in the aspect of COPD
development was investigated.
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